A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine

• Published in: Headache Vol. 55; no. 1; pp. 101 - 116
• Main Authors: Cady, Roger, Saper, Joel, Dexter, Kent, Manley, Heather R.
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.01.2015; Wiley Subscription Services, Inc; BlackWell Publishing Ltd
• Subjects: acute treatment; Administration, Intranasal - methods; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anesthetics, Local - administration & dosage; Bupivacaine - administration & dosage; Chronic Disease; chronic migraine; Double-Blind Method; Female; Headaches; Humans; Male; Middle Aged; Migraine; Migraine Disorders - therapy; Pain Measurement; Pilot Projects; preventive treatment; Research Submissions; Severity of Illness Index; sphenopalatine ganglion block; Sphenopalatine Ganglion Block - methods; Time Factors; Tx360; Young Adult; sphenopalatine ganglion block; chronic migraine; preventive treatment; Tx360; acute treatment

Objective To determine if repetitive sphenopalatine ganglion (SPG) blocks with 0.5% bupivacaine delivered through the Tx360® are superior in reducing pain associated with chronic migraine (CM) compared with saline. Background The SPG is a small concentrated structure of neuronal tissue that resides...